Dirk Waldschmidt

3.7k citations

68 papers · 924 indexed · h-index 17

Impact in

Oncology top 5%
- Pancreatic and Hepatic Oncology Research
- Cancer Immunotherapy and Biomarkers
Hepatology top 5%
- Hepatocellular Carcinoma Treatment and Prognosis

Papers in ⓘ

Oncology 51
- Pancreatic and Hepatic Oncology Research 33
- Colorectal Cancer Treatments and Studies 11
- Cancer Immunotherapy and Biomarkers 7
Hepatology 13
- Hepatocellular Carcinoma Treatment and Prognosis 10

Co-authors: Alexander Quaas (11 shared papers)Christiane J. Bruns (9 shared papers)Teresa Macarulla (6 shared papers)Oliver A. Cornely (4 shared papers)Anthony B. El-Khoueiry (8 shared papers)Michael von Bergwelt‐Baildon (4 shared papers)Robin Kate Kelley (6 shared papers)Stefan Boeck (16 shared papers)
Journals: Journal of Clinical Oncology (22 papers)Annals of Oncology (14 papers)BMC Cancer (3 papers)BMC Gastroenterology (2 papers)Clinical & Translational Oncology (1 paper)
Partner nations: Germany United States Spain

In The Last Decade

Dirk Waldschmidt

62 papers receiving 912 citations

Peers

Countries citing papers authored by Dirk Waldschmidt

Since Specialization

Citations

This map shows the geographic impact of Dirk Waldschmidt's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dirk Waldschmidt with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dirk Waldschmidt more than expected).

Fields of papers citing papers by Dirk Waldschmidt

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Dirk Waldschmidt. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dirk Waldschmidt. The network helps show where Dirk Waldschmidt may publish in the future.

Co-authors

The 25 scholars most cited alongside Dirk Waldschmidt, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Dirk Waldschmidt Line = papers co-authored together Dirk Waldschmidt links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 68 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Microwave ablation enhances tumor-specific immune response in patients with hepatocellular carcinoma Cancer Immunology Immunotherapy ·Katharina Leuchte, E Staib, Martin Thelen, Philipp Gödel, Axel Lechner, Peter Zentis, María A. García-Márquez, Dirk Waldschmidt, Rabi R. Datta, Roger Wahba, Christian Wybranski, Thomas Zander, Alexander Quaas, Uta Drebber, Dirk L. Stippel, Christiane J. Bruns, Michael von Bergwelt‐Baildon, Kerstin Wennhold, Hans Schlößer	2020	105
2	Ibrutinib in combination with nab-paclitaxel and gemcitabine for first-line treatment of patients with metastatic pancreatic adenocarcinoma: phase III RESOLVE study Annals of Oncology ·Margaret A. Tempero, Do‐Youn Oh, Josep Tabernero, Michele Reni, Eric Van Cutsem, Andrew Hendifar, Dirk Waldschmidt, Naureen Starling, Jean‐Baptiste Bachet, Heung Moon Chang, Joan Maurel, Rocio García‐Carbonero, Sara Lonardi, Lisa M. Coussens, Lawrence Fong, L. Claire Tsao, George W. Cole, Danelle F. James, Teresa Macarulla	2021	77
3	Final results from a phase II study of infigratinib (BGJ398), an FGFR-selective tyrosine kinase inhibitor, in patients with previously treated advanced cholangiocarcinoma harboring an FGFR2 gene fusion or rearrangement. Journal of Clinical Oncology ·Milind Javle, Sameek Roychowdhury, Robin Kate Kelley, Saeed Sadeghi, Teresa Macarulla, Dirk Waldschmidt, Lipika Goyal, Ivan Borbath, Anthony B. El-Khoueiry, Wei Peng Yong, Philip Agop Philip, Michael Bitzer, Suebpong Tanasanvimon, Ai Li, Amit Pande, Stacie Peacock Shepherd, Susan Moran, Ghassan K. Abou‐Alfa	2021	69
4	Randomized phase III trial of induction chemotherapy followed by chemoradiotherapy or chemotherapy alone for nonresectable locally advanced pancreatic cancer: First results of the CONKO-007 trial. Journal of Clinical Oncology ·Rainer Fietkau, Michael Ghadimi, Robert Grützmann, Uwe A. Wittel, Lutz Jacobasch, Waldemar Uhl, Roland S. Croner, Wolf O. Bechstein, Ulf P. Neumann, Dirk Waldschmidt, Stefan Boeck, Nicolas Moosmann, Anke Reinacher‐Schick, Henriette Golcher, Werner Adler, Sabine Semrau, Annett Kallies, Markus Hecht, Andrea Tannapfel, Helmut Oettle	2022	60
5	Clostridium Difficile Infection in Patients with Acute Myelogenous Leukemia and in Patients Undergoing Allogeneic Stem Cell Transplantation: Epidemiology and Risk Factor Analysis Biology of Blood and Marrow Transplantation ·Maria J. G. T. Vehreschild, David Weitershagen, Lena M. Biehl, Daniela Tacke, Dirk Waldschmidt, Ulrich Töx, Hilmar Wisplinghoff, Michael von Bergwelt‐Baildon, Oliver A. Cornely, Jörg Janne Vehreschild	2014	43
6	A phase 2 study of a novel transforming growth factor-beta (TGF-β1) receptor I kinase inhibitor, LY2157299 monohydrate (LY), in patients with advanced hepatocellular carcinoma (HCC). Journal of Clinical Oncology ·Sandrine Faivre, Armando Santoro, Robin Kate Kelley, Philippe Merle, Ed Gane, Jean‐Yves Douillard, Dirk Waldschmidt, Mary F. Mulcahy, Charlotte Costentin, Beatriz Mínguez, Pasqua Papappicco, Ivelina Gueorguieva, Ann Cleverly, D. Desaiah, Michael Lahn, Sophie Ameryckx, Karim A. Benhadji, Éric Raymond, Gianluigi Giannelli	2014	42
7	Antimicrobial prophylaxis in allogeneic bone marrow transplantation. Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Haematology and Oncology Annals of Oncology ·William Krüger, Julia Bohlius, Oliver A. Cornely, Hermann Einsele, Holger Hebart, Gero Massenkeil, Silke Schüttrumpf, Gerda Silling, Andrew J. Ullmann, Dirk Waldschmidt, Hans‐Heinrich Wolf	2005	41
8	Updated results from a phase II study of infigratinib (BGJ398), a selective pan-FGFR kinase inhibitor, in patients with previously treated advanced cholangiocarcinoma containing FGFR2 fusions Annals of Oncology ·Milind Javle, Robin Kate Kelley, Sameek Roychowdhury, K.H. Weiss, Ghassan K. Abou‐Alfa, Teresa Macarulla, Saeed Sadeghi, Dirk Waldschmidt, Andrew X. Zhu, Lipika Goyal, Mitesh J. Borad, Wei Peng Yong, Ivan Borbath, Anthony B. El-Khoueiry, P. A. Philip, Susan Moran, Yoon Ji Ye, Mary Ising, Nancy Lewis, Tanios Bekaii‐Saab	2018	33
9	Proposal for a definition of "Oligometastatic disease in pancreatic cancer" BMC Cancer ·Alexander Damanakis, Luisa M. Ostertag, Dirk Waldschmidt, Fabian Kütting, Alexander Quaas, Patrick Sven Plum, Christiane J. Bruns, Florian Gebauer, Felix Popp	2019	33
10	Randomized, double-blind, controlled study of glycyl-glutamine-dipeptide in the parenteral nutrition of patients with acute leukemia undergoing intensive chemotherapy Nutrition ·Christof Scheid, Karin Hermann, Gisela Kremer, Anja Holsing, Georg Heck, Michael Fuchs, Dirk Waldschmidt, Hans‐Joachim Herrmann, D. Söhngen, Volker Diehl, Achim Schwenk	2004	28
11	Antimicrobial therapy of febrile complications after high-dose chemotherapy and autologous hematopoietic stem cell transplantation—guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO) Annals of Hematology ·Florian Weißinger, Holger W. Auner, Hartmut Bertz, Dieter Buchheidt, Oliver A. Cornely, Gerlinde Egerer, Werner Heinz, Meinolf Karthaus, Michael Kiehl, William Krüger, Olaf Penack, Stefan Reuter, Markus Ruhnke, Michael Sandherr, Hans‐Jürgen Salwender, Andrew J. Ullmann, Dirk Waldschmidt, Hans H. Wolf	2012	28
12	Conversion rate in locally advanced pancreatic cancer (LAPC) after nab-paclitaxel/gemcitabine- or FOLFIRINOX-based induction chemotherapy (NEOLAP): Final results of a multicenter randomised phase II AIO trial Annals of Oncology ·Volker Kunzmann, Hana Algül, Eray Goekkurt, Gabriele Margareta Siegler, Uwe M. Martens, Dirk Waldschmidt, Uwe Pelzer, Elke Hennes, Martin Fuchs, Jens T. Siveke, Frank Kullmann, Stefan Boeck, Thomas J. Ettrich, Peter Ferenczy, R Keller, CT Germer, H. J. Stein, Ingo Hartlapp, Ingo Klein, Volker Heinemann	2019	21
13	Erlotinib 150 mg daily plus chemotherapy in advanced pancreatic cancer: an interim safety analysis of a multicenter, randomized, cross-over phase III trial of the ‘Arbeitsgemeinschaft Internistische Onkologie’ Anti-Cancer Drugs ·Stefan Boeck, Ursula Vehling‐Kaiser, Dirk Waldschmidt, E. Kettner, Angela Märten, Cornelia Winkelmann, Stefan Klein, G. Kojouharoff, Thomas Gauler, Ludwig Fischer von Weikersthal, Michael Clemens, Michael Geißler, Tim F. Greten, Susanna Hegewisch‐Becker, Sascha Neugebauer, Volker Heinemann	2009	20
14	Study protocol of an open-label, single arm phase II trial investigating the efficacy, safety and quality of life of neoadjuvant chemotherapy with liposomal irinotecan combined with Oxaliplatin and 5-fluorouracil/Folinic acid followed by curative surgical resection in patients with hepatic Oligometastatic adenocarcinoma of the pancreas (HOLIPANC) BMC Cancer ·Florian Gebauer, Alexander Damanakis, Felix Popp, Alexander Quaas, Fabian Kütting, K. Lutz, Swantje Held, Burkhard Deuß, T. Göser, Dirk Waldschmidt, Christiane J. Bruns	2021	19
15	Ibrutinib in combination with nab-paclitaxel and gemcitabine as first-line treatment for patients with metastatic pancreatic adenocarcinoma: results from the phase 3 RESOLVE study Annals of Oncology ·Margaret A. Tempero, Do‐Youn Oh, Teresa Macarulla, Michele Reni, Eric Van Cutsem, Andrew Hendifar, Dirk Waldschmidt, Naureen Starling, Jean‐Baptiste Bachet, Heung-Moon Chang, Joan Maurel, Sara Lonardi, Lisa M. Coussens, Lawrence Fong, Lee‐Ing Tsao, George W. Cole, Danelle F. James, Josep Tabernero	2019	16
16	AB051. P-19. A phase II study of infigratinib (BGJ398) in previously-treated advanced cholangiocarcinoma containing FGFR2 fusions HepatoBiliary Surgery and Nutrition ·Milind Javle, Robin Kate Kelley, Sameek Roychowdhury, Karl Weiss, Ghassan K. Abou‐Alfa, Teresa Macarulla, Saeed Sadeghi, Dirk Waldschmidt, Andrew X. Zhu, Lipika Goyal, Mitesh J. Borad, Wei Peng Yong, Ivan Borbath, Anthony B. El-Khoueiry, Philip Philip, Susan Moran, Yining Ye, Mary Ising, Nancy Lewis, Tanios Bekaii‐Saab	2019	16
17	Conko-006: a Randomized Double-Blinded Phase Iib-Study of Adjuvant Therapy with Gemcitabine + Sorafenib/Placebo for Patients with R1-Resection of Pancreatic Cancer Annals of Oncology ·M. Sinn, Torsten Liersch, Klaus Gellert, Hanno Riess, P. Stübs, Dirk Waldschmidt, Uwe Pelzer, Jens Stieler, Jana K. Striefler, Marcus Bahra, Bernd Dörken, Helmut Oettle	2014	16
18	Phase Ib study of regorafenib (REG) plus pembrolizumab (PEMBRO) for first-line treatment of advanced hepatocellular carcinoma (HCC). Journal of Clinical Oncology ·Anthony B. El-Khoueiry, Richard D. Kim, William Proctor Harris, Max W. Sung, Dirk Waldschmidt, Syma Iqbal, Xiao‐Jing Zhang, Keiko Nakajima, Peter R. Galle	2020	15
19	Updated results of a phase 1b study of regorafenib (REG) 80 mg/day or 120 mg/day plus pembrolizumab (PEMBRO) for first-line treatment of advanced hepatocellular carcinoma (HCC). Journal of Clinical Oncology ·Anthony B. El-Khoueiry, Richard D. Kim, William Proctor Harris, Max W. Sung, Dirk Waldschmidt, Roniel Cabrera, Vittorio Luigi Garosi, Hong Zebger‐Gong, Barbara J. Brennan, Ying A. Wang, U. Mueller, Tatiane Cristine Ishida, Peter R. Galle	2021	15
20	CONKO-005: Adjuvant therapy in R0 resected pancreatic cancer patients with gemcitabine plus erlotinib versus gemcitabine for 24 weeks—A prospective randomized phase III study. Journal of Clinical Oncology ·Marianne Sinn, Torsten Liersch, Klaus Gellert, Helmut Messmann, Wolf O. Bechstein, Dirk Waldschmidt, Lutz Jacobasch, Martin Wilhelm, Bettina Rau, Robert Grützmann, Arndt Weinmann, Georg Maschmeyer, Uwe Pelzer, Jens Stieler, Jana Kaethe Striefler, Β. Michael Ghadimi, Marcus Bahra, Helmut Oettle, Bernd Dörken, Hanno Riess	2015	15

About Dirk Waldschmidt

Dirk Waldschmidt is a scholar working on Oncology, Hepatology, Cancer Research, Pulmonary and Respiratory Medicine and Genetics, having authored 68 papers that have together received 924 indexed citations. Recurring topics across this work include Pancreatic and Hepatic Oncology Research (33 papers), Cancer Genomics and Diagnostics (18 papers), Cholangiocarcinoma and Gallbladder Cancer Studies (12 papers), Colorectal Cancer Treatments and Studies (11 papers), Hepatocellular Carcinoma Treatment and Prognosis (10 papers), Cancer Immunotherapy and Biomarkers (7 papers), Neuroendocrine Tumor Research Advances (7 papers) and Renal cell carcinoma treatment (6 papers). The work is most often cited by research in Oncology (607 citations), Hepatology (154 citations), Cancer Research (186 citations), Pulmonary and Respiratory Medicine (263 citations) and Immunology (109 citations). Dirk Waldschmidt has collaborated with scholars based in Germany, United States and Spain. Frequent co-authors include Alexander Quaas, Christiane J. Bruns, Teresa Macarulla, Oliver A. Cornely, Anthony B. El-Khoueiry, Michael von Bergwelt‐Baildon, Robin Kate Kelley, Stefan Boeck, Fabian Kütting and Thomas Zander. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, BMC Cancer, BMC Gastroenterology and Clinical & Translational Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact